Long-term effect of Dupilumab on acetylsalicylic acid (ASA) intolerance and its mechanisms in patients with non-steroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD)
This study is investigating Dupixent (Dupilumab), a medicine often used for certain allergic conditions, and its long-term effects on people who have Non-Steroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease (N-ERD). N-ERD means that common painkillers like aspirin or ibuprofen can make breathing problems worse. This research aims to see if taking Dupixent for six months helps people with N-ERD to tolerate aspirin better, allowing them to take higher doses without experiencing a reaction. Researchers will compare the maximum aspirin dose a participant can take before starting Dupixent, and then again after six months of treatment. The study also explores the scientific reasons behind any changes observed.
At a glance
What is this study about?
This study is looking into a condition called Non-Steroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease, or N-ERD for short. If you have N-ERD, taking common pain and fever medicines like aspirin or ibuprofen can trigger or worsen your breathing problems, such as asthma or nasal polyps. This can make it difficult to use pain relievers that many people take for granted.
The researchers are studying a medicine called Dupixent, which is already approved for other conditions like severe asthma, eczema, and chronic rhinosinusitis with nasal polyps. They want to find out if Dupixent can help people with N-ERD to safely take aspirin again, or at least tolerate a higher dose than they could before. This could significantly improve their quality of life, allowing them to use common medicines when needed without fear of a reaction.
The main goal is to measure whether the amount of aspirin a person can tolerate increases after taking Dupixent for six months. They will test different small doses of aspirin to find out exactly what each person can manage. The study also aims to understand the underlying biological changes happening in the body that might explain any improvements, looking at things like immune system markers and inflammation levels in the nose and blood.
Key takeaways
- This study evaluates Dupixent for people with N-ERD.
- It aims to see if Dupixent helps N-ERD patients tolerate aspirin.
- Participation involves taking Dupixent for six months.
- Aspirin tolerance will be carefully tested before and after treatment.
- Various tests will help understand the treatment's effects on the body.
Who may be eligible?
This study is looking for adults aged 18 years and older. Both men and women are welcome to take part. The most important requirement is that you must have been diagnosed with Non-Steroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease (N-ERD).
This means that taking medicines like aspirin or ibuprofen has caused your breathing problems to get worse in the past. If you don't have this specific condition, or if you are under 18, unfortunately, you won't be able to participate in this particular study.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have a diagnosis of N-ERD (reactions to aspirin/ibuprofen)?
- Are you willing to take Dupixent injections for 6 months?
- Are you able to attend regular study visits and undergo tests?
- Do you understand that this is a research study?
What does participation involve?
If you decide to take part, you will be given Dupixent (Dupilumab) as an injection, which comes in a pre-filled syringe. You'll use this medicine over a period of six months. Before starting the treatment and again after six months, you will have specific tests to see how much aspirin you can tolerate. This will involve carefully taking increasing small doses of aspirin (like 62.5mg, 125mg, 250mg, and 500mg) under medical supervision to find your safe limit.
Throughout the study, you will also have various other assessments. These include blood tests to check your immune system and allergy markers, skin prick tests for allergies, and tests to see if your sense of smell has changed. Researchers will also collect samples from your nose to look at inflammation and bacteria, and you'll complete questionnaires about your symptoms and quality of life. The exact number of visits will be explained by the study team, but expect regular check-ups over the six-month period to monitor your health and the effects of the treatment.
Potential risks and benefits
Locations (1)
- —UnverifiedAustria
Common questions
What is N-ERD?
N-ERD (Non-Steroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease) is a condition where common painkillers like aspirin or ibuprofen can worsen breathing problems like asthma or cause nasal polyps.
What is Dupixent?
Dupixent (Dupilumab) is a medicine often used to treat conditions like severe asthma, eczema, and nasal polyps, which are linked to certain allergic and inflammatory responses in the body.
How will they test my aspirin tolerance?
Under close medical supervision, you will be given very small, increasing doses of aspirin to carefully find the maximum amount you can take without experiencing a reaction.
How long will I take the study medicine?
You will be given Dupixent for a period of six months as part of this study.
Will I have to do a lot of tests?
Yes, there will be several tests, including blood checks, allergy tests, nasal samples, and questionnaires, to understand how the medicine is working and your overall health.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.